Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€102.26

€102.26

-1.530%
-1.58
-1.530%
€116.71

€116.71

 
22:26 / Tradegate WKN: 850103 / Symbol: ABT / Name: Abbott / Stock / Pharmaceuticals / Large Cap /
Latest predictions
€117.65
15:30
-1.39%
buy
€117.72
15:01
-1.39%
buy
€114.22
22.08.24
1.75%
buy
€132.17
29.07.24
6.09%
buy
€111.66
02.07.24
6.55%
buy
€114.98
04.06.24
7.87%
buy
Best running prediction
€109.69
19.10.23
16.17%
buy
Your prediction

Abbott Laboratories Stock

A loss of -1.530% shows a downward development for Abbott Laboratories.
The stock is an absolute favorite of our community with 21 Buy predictions and no Sell predictions.
With a target price of 116 € there is a slightly positive potential of 13.44% for Abbott Laboratories compared to the current price of 102.26 €.
So far the community has only identified positive things for Abbott Laboratories stock. The most positive votes were given for criterium "Brand".

Pros and Cons of Abbott Laboratories in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'

Performance of Abbott Laboratories vs. its peers

Security Change(%) 1w 1m 1y YTD 3y 5y
Abbott Laboratories -1.530% -2.194% 2.741% 9.449% 3.689% -4.311% 36.482%
Johnson & Johnson -1.200% 0.013% 3.457% -1.566% 5.664% 6.552% 26.561%
Elanco Animal Health Inc. -1.330% -0.850% -1.597% 18.297% -3.402% -52.733% -
Biogen Inc. 1.070% -1.550% -2.867% -24.958% -24.576% -30.487% -16.561%

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-12-01

Examining the financials of the pharmaceutical giant Abbott Laboratories, with its ticker symbol ABT, one can't help but form an initial impression tinged with intrigue. Abbott stands as a prominent entity in the healthcare sector, known for its diversified portfolio ranging from medical devices to nutritional products and branded generic medications. This diversity is reflected in its robust financial statements, showcasing the company's significant market presence and operational efficiency.

The sheer magnitude of Abbott's total assets, which hovered consistently above the $70 billion mark from 2020 to 2022, signals a company with considerable resources and a solid financial foundation. Across the same period, the evolution of its balance sheet reveals a healthy balance between liabilities and stockholder equity, pointing to sound financial management. The company's liquidity, as illustrated by its cash reserves, provides confidence in Abbott's ability to meet short-term obligations and invest in growth opportunities.

Profitability and Revenue Streams Abbott has demonstrated an admirable profit margin and a stable operating margin, hinting at its efficiency in converting revenue into profit and managing its operational expenses. The company's net income has shown relative growth, especially when evaluating the year-over-year rise from 2020 to 2022, indicating a consistent upward trajectory in profitability.

Comments

Prediction Buy
Perf. (%) -1.39%
Target price 117.651
Change
Ends at 19.09.25

Abbott Laboratories (NYSE: ABT) is now covered by analysts at Piper Sandler Companies. They set an "overweight" rating and a $131.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) -1.39%
Target price 117.717
Change
Ends at 19.09.25

Abbott Laboratories (NYSE: ABT) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $131.00 price target on the stock.
Ratings data for ABT provided by MarketBeat
Show more

Prediction Buy
Perf. (%) 1.31%
Target price 120.500
Change
Ends at 23.08.25

Hey there! So I've been digging into Abbott Laboratories lately, and I've got to say, I'm pretty impressed. Their FreeStyle Libre continuous glucose monitoring system is a game-changer for diabetes care. It's like having a personal diabetes assistant in your pocket! And get this - they added 250,000 new users last quarter alone. Talk about growth potential! Now, I know the stock's been a bit stagnant since the COVID testing boom faded, but don't let that fool you. Abbott's still crushing it across all their business segments. Their latest earnings report was solid, beating expectations on EPS and raising their full-year outlook. Sure, they just took a hit from that baby formula lawsuit, but I think that's more of a bump in the road than a roadblock. What really excites me is their new AVEIR dual chamber leadless pacemaker. It's the first of its kind in the world, and it's now available in Canada. Imagine a pacemaker that's a tenth the size of traditional ones, with no wires and less risk of complications. It's like they've shrunk the tech from Iron Man's chest piece! With their diverse portfolio and strong presence in emerging markets, I think Abbott's positioned for some healthy growth. The analysts seem to agree, with a bunch of 'em giving it a 'strong buy' rating. So, while I can't tell you what to do with your money, I'm feeling pretty bullish about Abbott's future. It might be time to give this stock a checkup in your portfolio!
Show more

News

Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?: https://g.foolcdn.com/editorial/images/790441/diabetes-patient-adjusting-device.jpg
Abbott Laboratories' Best Segment Just Got Even Better: Is the Stock a Buy?

Over the past few years, Abbott Laboratories' (NYSE: ABT) business has been a bit of a roller coaster. The pandemic disrupted its medical device business, but it was later able to smooth out those

3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold: https://g.foolcdn.com/editorial/images/789982/two-people-shaking-hands-at-a-meeting.jpg
3 Ultra-Safe Dividend Stocks for Retirees to Buy and Hold

Dividend growth stocks can make for ideal investment options whether you're a retiree or a long-term investor. The types of businesses that increase their payouts on a regular basis normally have a

2 Stocks That Are Passive Income Machines to Buy and Hold Forever: https://g.foolcdn.com/editorial/images/789836/doctor-holding-elderly-patients-hand.jpg
2 Stocks That Are Passive Income Machines to Buy and Hold Forever

Among the many corporations that pay a dividend, some do so unpredictably and irregularly. Others rarely raise their payouts -- perhaps once every few years -- while others still quickly resort to